Revolution Medicines, Inc. Warrant
Revolution Medicines, Inc. Warrant
- Market cap
- $35.42B
Your view on RVMDW
Overview
What the company does, where it operates, and who runs it.
About Revolution Medicines, Inc. Warrant
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark A. Goldsmith
- Headquarters
- 700 Saginaw Drive, Redwood City, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark A. Goldsmith
- Headquarters
- 700 Saginaw Drive, Redwood City, CA, US
Revolution Medicines, Inc. is a biopharmaceutical company in the clinical development phase, concentrating on creating innovative, precisely targeted therapies for cancers driven by RAS pathway dysregulation.
The firm's drug development portfolio features both RAS(ON) inhibitors, which are designed for potential use as single agents, in conjunction with other RAS(ON) inhibitors, or alongside RAS companion inhibitors and various therapeutic compounds.
Additionally, its pipeline includes dedicated RAS companion inhibitors intended for synergistic treatment approaches. Among its RAS(ON) inhibitors currently in Phase 1 clinical trials are RMC-6236 (targeting a broad spectrum of RAS mutations), RMC-6291 (specific to G12C), and RMC-9805 (for G12D).
Further compounds in preclinical or early development include RMC-5127 (for G12V), RMC-0708 (for Q61H), and RMC-8839 (for G13C), along with ongoing programs focused on G12R and other distinct molecular targets.
In the realm of RAS companion inhibitors, RMC-4630 is advancing through Phase 2 clinical assessment, while RMC-5552 is undergoing Phase 1 evaluation. Revolution Medicines, Inc. was founded in 2014 and operates from its headquarters in Redwood City, California.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Revolution Medicines, Inc. Warrant. Starting points for Revolution Medicines, Inc. Warrant: EPS -$8.70, beta 1.40 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Revolution Medicines, Inc. Warrant. Trailing twelve-month EPS for Revolution Medicines, Inc. Warrant stands at -$8.70. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Revolution Medicines, Inc. Warrant. Revolution Medicines, Inc. Warrant has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ARUXFAcrux Limited | Healthcare | OTC | $1.8M | ||
| ARVNArvinas, Inc. | Healthcare | NASDAQ | $423.0M | ||
| ARWRArrowhead Pharmaceuticals, Inc. | Healthcare | NASDAQ | $5.8B | ||
| ASBPAspire Biopharma Holdings, Inc. | Healthcare | NASDAQ | $822,602 | ||
| ASBPWAspire Biopharma Holdings, Inc. | Healthcare | NASDAQ | $121,920 | ||
| ASCLFAscletis Pharma Inc. | Healthcare | OTC | $2.1B | ||
| ASEP.CNAsep Medical Holdings Inc | Healthcare | CNQ | — | ||
| ASMBAssembly Biosciences, Inc. | Healthcare | NASDAQ | $454.4M | ||
| ASNDAscendis Pharma A/S | Healthcare | NASDAQ | $16.6B | ||
| ASPEAspen Neuroscience Inc. | Healthcare | NASDAQ | $361.2M | ||
| ASPHFAscentage Pharma Group International | Healthcare | OTC | $3.2B | ||
| ATAIAtai Life Sciences N.V. | Healthcare | NASDAQ | $2.7B | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Revolution Medicines, Inc. Warrant executives and directors. Shares of Revolution Medicines, Inc. Warrant have traded between $0.39 and $11.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Revolution Medicines, Inc. Warrant. Coverage tracks Revolution Medicines, Inc. Warrant within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Revolution Medicines, Inc. Warrant.